Group 1 - The core viewpoint of the article highlights the successful debut of Jinfang Pharmaceutical on the Hong Kong Stock Exchange, with a significant stock price increase of 106.5% on its first trading day, closing at HKD 42.1 per share and achieving a total market capitalization of HKD 15.03 billion [1] - Jinfang Pharmaceutical, established in 2017, focuses on the development of innovative therapies for oncology, autoimmune, and inflammatory diseases, with a pipeline that includes 8 candidate products, 5 of which are in clinical development [1] - Financial data indicates that the company's revenues for the years 2023-2024 and the first four months of 2025 were HKD 73.734 million, HKD 105 million, and HKD 82.149 million respectively, while the losses for the same periods were HKD 508 million, HKD 678 million, and HKD 66.624 million [1]
劲方医药登陆港交所，上市首日收涨106.5%